CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 80 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,346,834 | +297.9% | 157,400 | +192.2% | 0.00% | – |
| Q2 2023 | $589,844 | -7.8% | 53,867 | -26.6% | 0.00% | – |
| Q1 2023 | $640,048 | -64.3% | 73,400 | -74.3% | 0.00% | -100.0% |
| Q4 2022 | $1,791,565 | +3.4% | 285,736 | -42.3% | 0.00% | 0.0% |
| Q3 2022 | $1,733,000 | +29.0% | 495,238 | +8.8% | 0.00% | 0.0% |
| Q2 2022 | $1,343,000 | +1256.6% | 455,265 | +1347.2% | 0.00% | – |
| Q1 2022 | $99,000 | -48.7% | 31,459 | -44.9% | 0.00% | – |
| Q4 2021 | $193,000 | +66.4% | 57,142 | +79.7% | 0.00% | – |
| Q3 2021 | $116,000 | -27.0% | 31,797 | -12.8% | 0.00% | – |
| Q2 2021 | $159,000 | -70.7% | 36,481 | -69.4% | 0.00% | – |
| Q1 2021 | $542,000 | -26.8% | 119,370 | -7.4% | 0.00% | – |
| Q4 2020 | $740,000 | +183.5% | 128,944 | +257.5% | 0.00% | – |
| Q3 2020 | $261,000 | -80.3% | 36,070 | -90.5% | 0.00% | -100.0% |
| Q2 2020 | $1,322,000 | +139.9% | 378,867 | +1.9% | 0.00% | – |
| Q1 2020 | $551,000 | +231.9% | 371,902 | +340.1% | 0.00% | – |
| Q4 2019 | $166,000 | -79.5% | 84,509 | -46.6% | 0.00% | – |
| Q3 2019 | $811,000 | +51.3% | 158,386 | +111.7% | 0.00% | – |
| Q2 2019 | $536,000 | -50.1% | 74,800 | -7.6% | 0.00% | – |
| Q1 2019 | $1,075,000 | +289.5% | 80,976 | +130.6% | 0.00% | – |
| Q4 2018 | $276,000 | -55.5% | 35,117 | -37.2% | 0.00% | – |
| Q3 2018 | $620,000 | -67.4% | 55,952 | -60.5% | 0.00% | -100.0% |
| Q2 2018 | $1,900,000 | +353.5% | 141,581 | +339.3% | 0.00% | – |
| Q1 2018 | $419,000 | +423.8% | 32,232 | +271.8% | 0.00% | – |
| Q4 2017 | $80,000 | +233.3% | 8,670 | +189.0% | 0.00% | – |
| Q3 2017 | $24,000 | -11.1% | 3,000 | -36.7% | 0.00% | – |
| Q2 2017 | $27,000 | +68.8% | 4,738 | +26.0% | 0.00% | – |
| Q1 2017 | $16,000 | +33.3% | 3,759 | -46.8% | 0.00% | – |
| Q4 2016 | $12,000 | +100.0% | 7,069 | +135.6% | 0.00% | – |
| Q3 2016 | $6,000 | -40.0% | 3,000 | -51.0% | 0.00% | – |
| Q2 2016 | $10,000 | -44.4% | 6,128 | -9.5% | 0.00% | – |
| Q2 2015 | $18,000 | +500.0% | 6,771 | +1958.1% | 0.00% | – |
| Q4 2014 | $3,000 | – | 329 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |